Midatech’s FY results are broadly in line with expectations, following the trading update in January. The acquisition of NASDAQ-listed DARA Biosciences in Dec 2015, which brought a US sales team and a portfolio of mainly oncology support products, is expected to drive significant revenue growth in the years ahead; Phase II results for MidaForm™- Insulin-PharmFilm™ remain expected in Q2 2016; and IND enabling studies for the company’s brain cancer and liver cancer programmes are expected to comme ....